Agency for Care Effectiveness (ACE)

Name

Agency for Care Effectiveness (ACE)

Legal name

Agency for Care Effectiveness

Website

https://ace-hta.gov.sg

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

51–100 employees

Ownership category

akta.pro rank

Product category

Health Technology Assessment (HTA) and Clinical Guidelines Services

NAICS

Other Scientific and Technical Consulting Services (541690), Testing Laboratories and Services (54138)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Real-World Evidence (RWE), HEOR & Epidemiology CROs (HLAGAAAK)

akta.pro secondary industries

Clinical Trials Authorization & Oversight (GCP) (HLAJADAF), Chronic Disease & NCD Program Evaluation (e.g., diabetes/CVD/cancer) (HLAJANAG)

Keywords

• Health technology assessment
• Clinical guidelines development
• Evidence-based medicine
• Healthcare cost-effectiveness
• Drug and medical technology guidance

Headquarters

HQ city

Singapore

HQ country

Singapore

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Others

Revenue model

1. Government Funding: ACE is established by the Ministry of Health and funded by the Singapore government. The agency does not generate commercial revenue but operates as a statutory body conducting public health technology assessments to support healthcare decision-making.

Distribution channels3 records

Marketing channels7 records

Core offering

ACE conducts health technology assessments evaluating the clinical effectiveness, safety, and cost-effectiveness of drugs, vaccines, gene therapies, medical devices, diagnostics, and procedures, producing technology guidances that inform MOH subsidy decisions. It also develops ACE Clinical Guidelines (ACGs) and maintains the ACE Repository for Clinical Guidelines (ARCG), supported by its Guidelines for Guidelines (G4G) standards, while delivering education resources for healthcare professionals and patients.

Product overview

ACE is Singapore's national health technology assessment (HTA) and clinical guidelines agency. The organization operates as a unified platform providing HTA evaluations, ACE Clinical Guidelines (ACGs), Technology Guidance (both drug and medical technology), the ACE Repository for Clinical Guidelines (ARCG), and educational resources including video resources and ACE Insights publications. The core offerings include health technology assessments that inform funding decisions, evidence-based clinical guidelines developed with multidisciplinary experts, drug and medical technology guidance for subsidy recommendations, and consumer education resources for patients and caregivers.

Differentiator

Problem solved

Functional benefit

Products and services

• Health Technology Assessment (HTA) Technical evaluations informing public funding decisions for health technologies, covering clinical effectiveness, safety, and cost-effectiveness, supporting value-based pricing negotiations and tracking of utilisation and outcomes.
• ACE Clinical Guidelines (ACGs) Concise, evidence-based clinical practice recommendations developed with multidisciplinary groups of local experts, serving as a common starting point nationally for clinical decision-making by healthcare professionals.
• ACE Repository for Clinical Guidelines (ARCG) Resource library housing ACE Clinical Guidelines (ACGs) and other high-quality local guidelines methodologically validated by ACE, for use by healthcare professionals and institutions.
• Medical Technology Guidance Evidence-based recommendations on medical devices, procedures, and diagnostics published by the MOH Medical Technology Advisory Committee to inform public funding and subsidy decisions.
• Drug Guidance Evidence-based recommendations on drugs, vaccines, and gene therapies published by the MOH Drug Advisory Committee to inform subsidy and public funding decisions.
• Guidelines for Guidelines (G4G) ACE's minimum standards and principles for external clinical guideline development in Singapore's healthcare setting, providing quality criteria applied across methodologies.
• Healthcare Consumer Education Information, factsheets, and tools for patients and caregivers to understand medical conditions, treatment options, and participate in shared decision-making with clinicians.

Quantifiable outcome

• Over $2 billion in cumulative healthcare cost savings from 2016-2024
• +1 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

Yes

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Eight partnerships are on record, tiered core and minor.

• ACE Consumer PanelcoreStrategic or Co-development Partner · 1 April 2026The ACE Consumer Panel supports meaningful patient involvement across ACE's work and other MOH initiatives. The Panel comprises individuals from local patient organisations, and leaders of patient engagement efforts in healthcare clusters or academic institutions. Members include representatives from the Ostomy Association of Singapore, Cerebral Palsy Alliance of Singapore, Singapore Cancer Society, Diabetes Singapore, Brain Tumour Society Singapore, and other patient organisations. Current Panel members appointed for 2-year term from 1 Apr 2026 to 31 Mar 2028.
• International Advisory Panel (IAP)coreStrategic or Co-development Partner · 1 March 2026The ACE International Advisory Panel comprises international experts who advise ACE on health technology assessments, healthcare guideline development, and education to support informed decision-making. Members include experts from NICE UK, Canada's Drug Agency, Pharmac New Zealand, Monash University, Newcastle University, McMaster University, and other leading institutions. Members serve a three-year term from 1 Mar 2026 to 28 Feb 2029.
• Health Technology Advisory Council (HTAC)coreStrategic or Co-development Partner · 1 April 2025HTAC was formed from 1 April 2025 as an independent professional body responsible for providing evidence-based recommendations to MOH for high-cost, high-impact health technologies. HTAC reviews assessments made by DAC and MTAC regarding clinical and cost effectiveness of treatments and provides funding recommendations to MOH.
• Value-Based Healthcare Conference PartnersminorGTM or Marketing Partner · 1 September 2024Annual Value-Based Healthcare Conference held in Singapore bringing together local and international delegates to share best practices for better patient outcomes. Features pre-conference workshops on clinical guidelines development and other HTA topics.
• MOH Drug Advisory Committee (DAC)coreStrategic or Co-development PartnerDAC is responsible for providing evidence-based recommendations to MOH for public funding of drugs. DAC prioritises drug applications, appraises clinical and cost-effectiveness, provides listing recommendations, and monitors impact of ACE guidance on prescribers' behaviours.
• MOH Medical Technology Advisory Committee (MTAC)coreStrategic or Co-development PartnerMTAC is responsible for providing evidence-based recommendations to MOH for public funding of medical technologies. MTAC identifies and prioritises technologies for evaluation, deliberates on evidence, recommends subsidy conditions, and monitors impact on prescribers' behaviours.
• Singapore Healthcare Clusters and InstitutionscoreImplementation/ SI/ Consulting PartnerACE develops and implements adoption strategies within public healthcare institutions to drive uptake of technology guidances. This includes working with healthcare clusters including NUHS, NHG, SingHealth, and SHS to facilitate guideline adoption and clinical practice change.
• Healthcare Professional Societies and Academic InstitutionsminorStrategic or Co-development PartnerACE collaborates with healthcare professional societies and academic institutions including universities for ACE Clinical Guideline Expert Groups, continuing professional education, and research partnerships. Expert Groups include multidisciplinary local experts representing relevant specialties and practice settings.

Scale indicators4 records

Recent moves5 records

Expansion highlights5 records

Market position

Strengths4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/agency-for-care-effectiveness

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Agency for Care Effectiveness (ACE)